ELV 10-K Annual Reports

Elevance Health, Inc. (ELV) reported a year of increased revenue and strategic acquisitions, but saw a slight decrease in net income for the year ended December 31, 2025. Total operating revenue grew by 12.8% to $197.6 billion, driven by premium rate increases across its Health Benefits segment, growth in Medicare Advantage, and the impact of acquisitions. However, shareholders' net income declined by 5.3% to $5.66 billion, or $25.21 per diluted share, primarily due to higher medical cost trends within the Health Benefits segment and increased investments in technology and workforce. The company experienced a 1.1% decrease in total medical membership, largely due to Medicaid redeterminations and attrition in other segments, partially offset by growth in Medicare Advantage and Individual businesses. Key strategic moves during the year included the acquisition of Centers and CareBridge, aimed at strengthening its Medicaid and long-term care offerings and its Carelon Services segment. The company also managed its capital effectively, repurchasing shares and paying dividends, while maintaining a strong liquidity position. Looking ahead, Elevance Health is navigating evolving regulatory landscapes and persistent medical cost pressures.

Elevance Health, Inc. (ELV) reported a stable financial performance for the year ended December 31, 2024, with total operating revenue increasing by 2.9% to $175.2 billion. This growth was primarily driven by premium rate increases across its health plans, expansion in its CarelonRx segment, and contributions from recent acquisitions. Net income remained relatively flat year-over-year at $5.97 billion, reflecting a slight decrease of 0.3%. Diluted Earnings Per Share (EPS) saw a modest increase of 1.8% to $25.68, attributed to a reduction in diluted shares outstanding due to share repurchases. The company experienced a notable decline in Medicaid membership (down 15.1%), largely due to eligibility redeterminations and market exits, which impacted benefit expenses. However, this was partially offset by growth in Employer Group fee-based, Individual, and FEP businesses. Strategic initiatives are ongoing, including the integration of acquired businesses like Paragon Healthcare and CareBridge, and the divestiture of life and disability businesses. Management is focused on optimizing operations and managing healthcare costs through value-based care models and medical management programs. The company maintains a strong liquidity position and ended the year with $35.7 billion in cash, cash equivalents, and investments. Key risks identified include managing healthcare costs, regulatory changes, and cybersecurity threats.

Elevance Health, Inc. (ELV) reported strong revenue growth for the fiscal year ended December 31, 2023, with total operating revenue increasing by 9.3% to $170.2 billion. This growth was primarily driven by premium rate increases in its Health Benefits segment and expansion in its CarelonRx pharmacy business, including the acquisition of BioPlus. Net income saw a modest increase of 1.7% to $5.99 billion, resulting in diluted earnings per share of $25.22, up 3.9%. The company experienced a decline in Medicaid membership due to the resumption of eligibility redeterminations, but this was offset by growth in Individual Public Exchange and Medicare Advantage membership. Elevance Health continues to manage healthcare costs effectively through various programs and pricing strategies, while also investing in digital transformation and expanding its Carelon brand for healthcare services. The company's financial health remains solid, with a debt-to-capital ratio of 38.9% as of December 31, 2023. Elevance Health also announced strategic acquisitions and a pending divestiture, signaling ongoing efforts to refine its business portfolio and enhance its market position.

Elevance Health, Inc. (ELV) reported strong performance for the fiscal year ended December 31, 2022, demonstrating resilience and strategic growth. The company experienced a significant increase in total operating revenue, primarily driven by robust membership growth in its Government Business segment, particularly within Medicaid, bolstered by the temporary suspension of eligibility recertifications due to the COVID-19 pandemic. Acquisitions in the Medicaid space also contributed positively to revenue. While net income saw a slight decrease year-over-year, largely due to realized losses on financial instruments and increased amortization, the company maintained a strong operating gain across all segments. Elevance Health continues to focus on its transformation into a lifetime, trusted health partner, expanding its brand portfolio and optimizing its business operations. The company also highlighted its commitment to shareholder returns through share repurchases and dividends, underpinned by solid liquidity and capital resources. Looking ahead, Elevance Health is strategically positioned to benefit from ongoing healthcare trends, including potential growth in the individual exchange market as Medicaid eligibility recertifications resume. The company's diversification across commercial, government, and specialty segments, coupled with its integrated capabilities in pharmacy benefits management (CarelonRx) and health services (Carelon Services), provides a solid foundation for future expansion and profitability. Investors should monitor the company's integration of recent acquisitions and its continued progress in achieving its 'whole health' strategy.

Elevance Health, Inc. (formerly Anthem, Inc.) reported strong financial performance for the year ended December 31, 2021, characterized by significant revenue growth and increased net income. Total operating revenue rose by 13.4% to $136.9 billion, driven by membership growth, particularly in the Government Business segment (Medicaid and Medicare), and contributions from its IngenioRx PBM business. Net income saw a substantial increase of 33.3% to $6.1 billion, resulting in diluted earnings per share (EPS) of $24.73. This growth was supported by strong operating gains across all business units, the absence of certain litigation accrual charges from the prior year, and increased investment income. The company expanded its market participation in the ACA Public Exchange, reflecting confidence in market sustainability. Despite ongoing challenges related to healthcare cost trends and regulatory complexities, Elevance Health demonstrated robust operational execution and strategic growth initiatives, including key acquisitions, positioning it well for future performance.

Elevance Health, Inc. (formerly Anthem Inc.) reported strong operational and financial performance for the fiscal year ending December 31, 2020. The company demonstrated robust revenue growth, driven by expansion in its Government Business segment (Medicare and Medicaid) and the successful integration of its Pharmacy Benefit Manager (PBM) services through IngenioRx. Despite the challenges posed by the COVID-19 pandemic, Elevance Health maintained a solid membership base, particularly in its government programs, benefiting from increased eligibility and utilization. The company's strategic diversification into integrated health services, highlighted by the acquisition of Beacon Health Options, is progressing well and is expected to contribute to long-term growth. Financially, the company reported total revenues of $121.9 billion, with net income of $4.6 billion. While facing increased COVID-19 related expenses, including testing and treatment, the company managed its benefit expense ratio effectively, partly due to reduced utilization of non-COVID-19 services. Elevance Health also actively managed its capital through share repurchases and dividend payments, reflecting a commitment to shareholder value. The company's balance sheet remains strong, with significant cash and investments, supporting its ongoing operations and strategic initiatives. Investors should note the ongoing regulatory landscape and the company's proactive approach to managing evolving healthcare policies and market dynamics.

Elevance Health, Inc. (formerly Anthem, Inc.) reported strong performance for the fiscal year ended December 31, 2019. The company experienced significant growth in operating revenue, driven by higher premiums and increased administrative fees, primarily from its Government and Commercial & Specialty business segments. Net income also saw a substantial increase, reflecting improved operating results and the benefits from the launch of its pharmacy benefits manager, IngenioRx. The company highlighted membership growth, particularly in its Medicaid and Medicare businesses, and a strategic focus on expanding its integrated health services and diversifying its revenue streams. Financially, Elevance Health maintained a robust balance sheet with substantial cash and investments. The company demonstrated effective management of its capital through share repurchases and dividend payments. Key strategic initiatives for the year included the ongoing development of IngenioRx and the pending acquisition of Beacon Health Options, Inc., signaling a commitment to enhancing its health services capabilities and providing more comprehensive, personalized care solutions for its members. The company is well-positioned to navigate the evolving healthcare landscape, balancing growth with efficient capital allocation.

Elevance Health, Inc. (formerly Anthem, Inc.) reported solid performance for the year ended December 31, 2018, with total revenues reaching $92.1 billion. The company demonstrated growth in its Government Business segment, largely driven by acquisitions and favorable Medicare and Medicaid membership trends. However, the Commercial & Specialty Business segment experienced a revenue decrease, primarily due to the company's strategic reduction in participation within the Individual ACA-compliant marketplaces. Financially, net income was $3.75 billion, a slight decrease from the previous year, impacted by higher income tax expenses and net realized losses on investments. Despite this, the company maintained a strong balance sheet and liquidity position. Key operational highlights include the strategic acquisition of America's 1st Choice to bolster its Medicare Advantage offerings and the ongoing development of IngenioRx as a new pharmacy benefits manager. The company also continues to navigate the evolving regulatory landscape, particularly concerning the Affordable Care Act (ACA).

Elevance Health, Inc. (formerly Anthem, Inc.) reported strong financial performance for the year ended December 31, 2017. Total operating revenue increased by 5.8% to $89.1 billion, driven by higher premium revenue across its Government and Commercial & Specialty Business segments. Net income saw a substantial increase of 55.6% to $3.8 billion, primarily due to lower income tax expenses and improved investment activities. Diluted earnings per share (EPS) also rose significantly by 55.8% to $14.35. The company's medical membership grew slightly to 40.2 million, with notable increases in Medicare and Local Group memberships, partially offset by decreases in Individual and National Accounts. The company continued its growth strategy through strategic acquisitions, notably the acquisition of HealthSun in December 2017, which is expected to bolster its Medicare Advantage and dual-eligible populations. Elevance Health also made progress in establishing its own pharmacy benefits manager, IngenioRx, and secured a five-year agreement with CVS Health to manage these services starting in 2020, coinciding with the conclusion of its current agreement with Express Scripts. This strategic move towards vertical integration in pharmacy benefits management signals a move to control costs and enhance service offerings. Despite a challenging regulatory environment, particularly concerning the Affordable Care Act (ACA), Elevance Health demonstrated resilience and strategic focus. The company highlighted its reduced participation in the Individual ACA-compliant marketplaces for 2018, focusing only on rating regions with a higher degree of confidence in market sustainability. This demonstrates a disciplined approach to managing risks associated with market uncertainties. Overall, the filing indicates a robust operational performance, strategic expansion initiatives, and a proactive approach to navigating the evolving healthcare landscape.

Elevance Health, Inc. (formerly Anthem, Inc.) reported strong revenue growth in 2016, driven by increases in both its Government and Commercial/Specialty segments. The company highlighted a significant rise in Medicaid membership and sustained growth in National Accounts. Despite overall revenue gains, net income saw a slight decline due to increased transaction costs related to the pending acquisition of Cigna, higher interest expenses, and reduced net earnings from investments. The company's financial performance was significantly impacted by the ongoing legal and regulatory challenges surrounding the proposed Cigna merger, which introduced considerable uncertainty and transaction-related expenses. Elevance Health remains focused on its strategy of organic growth, strategic acquisitions, and efficient capital utilization, while navigating the evolving healthcare landscape influenced by regulatory changes and market dynamics.

Elevance Health, Inc. (formerly Anthem, Inc.)'s 2015 10-K report highlights a year of significant growth and strategic positioning, marked by a robust increase in total operating revenue to $78.4 billion, driven primarily by expansion in its Government Business segment, particularly Medicaid and Medicare, and by rate increases across its portfolio. The company served 38.6 million medical members by year-end. A pivotal event disclosed is the pending acquisition of Cigna Corporation, announced in July 2015, which is expected to create a premier health benefits company. This strategic move underscores the company's commitment to scale and transformation in the healthcare landscape. Despite a slight decrease in net income to $2.56 billion, the company reported solid diluted earnings per share of $9.38, reflecting effective share repurchases that reduced the share count. The company's financial health remains strong, with significant operating cash flow and substantial investments, positioning it to navigate the evolving healthcare market and pursue future growth opportunities.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported strong performance for the fiscal year ended December 31, 2014. The company experienced a 4.0% increase in total operating revenue, reaching $73.0 billion, driven primarily by growth in its Government Business segment, particularly Medicaid and Medicare programs, and to a lesser extent, its Commercial and Specialty Business. Net income saw a 3.2% increase to $2.6 billion, with diluted earnings per share (EPS) rising by 9.6% to $8.99. This growth was supported by an effective share repurchase program, which reduced the number of outstanding shares and boosted EPS. The company also demonstrated solid operating cash flow, indicating strong financial health. Key strategic initiatives for 2014 included expanding its government business, notably through the acquisition of Simply Healthcare Holdings, Inc., which further solidified its position in the Medicaid and Medicare markets in Florida. Elevance Health also continued to navigate the evolving healthcare landscape, including the implementation of the Affordable Care Act (ACA), focusing on product innovation and expanding its network collaborations. The company's robust financial position, coupled with strategic growth initiatives and effective management of healthcare costs, positions it well for continued performance in the competitive health insurance market.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported strong revenue growth in 2013, driven primarily by its Government Business segment, largely due to the acquisition of Amerigroup. However, net income saw a slight decrease compared to the previous year, impacted by the divestiture of its 1-800 CONTACTS business, preparation costs for the Affordable Care Act (ACA), and debt extinguishment losses. The company experienced a slight decline in total medical membership, with notable decreases in Medicare and Individual segments, partially offset by growth in Medicaid. Management highlighted strategic repositioning in certain Medicare Advantage plans and continued focus on integrating acquisitions, managing healthcare costs, and enhancing digital member interactions. The company continued its capital return strategy through dividends and share repurchases.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported strong financial performance for the fiscal year ended December 31, 2012. The company experienced an increase in total operating revenue to $60.73 billion, a 1.4% rise year-over-year, primarily driven by membership growth in its Medicare Advantage and State-Sponsored businesses, as well as contributions from recent acquisitions. Net income saw a marginal increase of 0.3% to $2.66 billion, with diluted earnings per share (EPS) rising significantly by 12.8% to $8.18. This EPS growth was attributed to a reduction in outstanding shares due to active share repurchase programs and the modest net income increase. The company also highlighted its strategic acquisitions, including Amerigroup and 1-800 CONTACTS, which are expected to bolster its capabilities in government-backed programs and diversify revenue streams. Looking ahead, Elevance Health expressed its commitment to organic growth, strategic acquisitions, and efficient capital deployment, aiming to enhance shareholder value while navigating the evolving healthcare landscape. The company's financial health remains robust, with significant cash reserves and available credit facilities to support its growth initiatives.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported strong financial performance for the fiscal year ended December 31, 2011. The company experienced a 3.7% increase in total operating revenue to $59.9 billion, driven by premium rate increases and membership growth in its Senior business. Net income, however, saw a slight decrease of 8.3% to $2.6 billion, primarily due to lower operating results in the Consumer segment, partially offset by improvements in the Commercial and Other segments. Despite the dip in net income, diluted earnings per share (EPS) rose by 4.5% to $7.25, aided by a reduction in outstanding shares due to a robust share repurchase program. The company's strategic acquisition of CareMore in August 2011 positions it for future growth in the senior care market. Management highlighted a commitment to enhancing member value through innovative care management programs and technology investments. Looking ahead, Elevance Health aims to drive growth organically and through strategic acquisitions, focusing on earnings per share growth and efficient capital deployment.

Elevance Health, Inc. (ELV), formerly WellPoint, Inc., reported for the year ended December 31, 2010, total operating revenue of $57.8 billion, a decrease of 5% from the previous year. This decline was attributed to factors such as unfavorable economic conditions leading to membership declines in certain segments, the conversion of some fully-insured accounts to self-funded status, and the sale of its pharmacy benefits management (PBM) business. Net income for 2010 was $2.9 billion, a significant decrease of 39% from 2009, largely due to the absence of a substantial gain on the PBM sale in the prior year and higher operating results in some segments being offset by increased costs. The company experienced a net decrease in medical membership of 347,000 members, bringing the total to 33.3 million. Despite the overall membership decline, the company saw growth in its National Accounts, FEP, Senior, and State-Sponsored segments. The shift towards self-funded plans continued, with a 7% increase in self-funded membership, while fully-insured membership decreased by 11%. The company continued its significant share repurchase program, returning substantial capital to shareholders. Investors should note the ongoing impact of healthcare reform legislation, such as the Patient Protection and Affordable Care Act (PPACA), which is expected to significantly shape the future operating landscape and regulatory environment for the company.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported solid financial performance for the year ended December 31, 2009, with total operating revenue of $60.8 billion, a slight decrease of 1% from the previous year, primarily attributed to membership declines in its Commercial and Consumer businesses due to economic conditions. However, net income saw a substantial increase of 91% to $4.7 billion, resulting in diluted earnings per share of $9.88, up from $4.76 in 2008. This significant profit growth was largely driven by a substantial $2.4 billion after-tax gain from the sale of its Prescription Benefits Management (PBM) business to Express Scripts. Strategically, the company continued to focus on growth through organic membership gains and strategic acquisitions, while also actively managing its capital through a robust share repurchase program. The company also highlighted its efforts to manage healthcare costs through various medical management programs and its commitment to improving the quality of care. Despite facing membership headwinds due to the economic downturn, Elevance Health demonstrated strong profitability, driven by operational efficiencies and a significant one-time gain from the PBM divestiture.

Elevance Health, Inc. (ELV), formerly WellPoint, Inc., reported robust performance in its 2008 Annual Report, demonstrating growth in total operating revenue to $61.6 billion, a 2% increase year-over-year, driven by premium rate adjustments across its medical lines and growth in its Medicare Advantage business. Despite increased medical costs impacting net income, which decreased by 26% to $2.5 billion, the company maintained a strong liquidity position and continued its share repurchase program. The company highlighted its significant market presence, serving 35 million members nationwide, and its diversified product offerings across commercial, consumer, and other segments. Strategic focus remains on organic growth, targeted acquisitions, and enhancing value-based care initiatives. The company's operational results were influenced by several key factors, including a 4% increase in benefit expenses primarily due to higher medical costs, and a 4% rise in selling, general, and administrative expenses, largely attributed to increased compensation and severance costs. However, these were partially offset by premium increases and growth in self-funded membership. The report also details the company's ongoing efforts in care management, technology integration, and quality initiatives, underscoring its commitment to improving healthcare value and member outcomes. The company's substantial investments in intangible assets, representing 46% of total assets, reflect its acquisitive growth strategy. Looking ahead, Elevance Health is positioned to navigate the evolving healthcare landscape by focusing on operational efficiency, strategic growth, and adapting to regulatory changes. The company's financial health remains solid, supported by a strong balance sheet and consistent operational cash flow, enabling continued investment in its business and return of capital to shareholders through its stock repurchase program. Investors should note the company's significant presence in both government-sponsored programs (Medicare and Medicaid) and commercial markets, offering a diversified revenue base.

Elevance Health (ELV), formerly WellPoint, Inc., reported strong financial performance in its 2007 annual report, with total operating revenue reaching $60.1 billion, a 7% increase over the prior year. This growth was primarily driven by premium rate increases, expansion in state-sponsored programs, and growth in Medicare Advantage products. Diluted earnings per share (EPS) rose by 15% to $5.56, demonstrating the company's successful execution of its EPS growth strategy through profitable enrollment, innovative offerings, and disciplined pricing. The company highlighted its significant stock repurchase program, having repurchased approximately 76.9 million shares for $6.2 billion during 2007, reflecting a commitment to returning capital to shareholders and prudent use of surplus capital. Strategic acquisitions, such as the purchase of Imaging Management Holdings, LLC, also contributed to the company's growth and alignment with its strategy to lead in affordable quality care. The company's robust membership base of 34.8 million medical members as of December 31, 2007, across various customer types, positions it well for continued market leadership.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported a strong financial performance for the fiscal year ending December 31, 2006. The company experienced significant revenue growth, primarily driven by the acquisition of WellChoice, Inc. and organic growth across its various product lines. Management highlighted a 22% increase in diluted earnings per share (EPS), exceeding their growth target. The company continued its strategy of profitable enrollment growth, disciplined pricing, cost optimization, and effective cash flow utilization. Elevance Health remains focused on expanding its market presence through both organic growth and strategic acquisitions, emphasizing geographic diversity and leveraging its strong Blue Cross and Blue Shield brand recognition. The company's diversified membership base, spanning commercial, individual, senior, and government markets, positions it well to navigate the evolving healthcare landscape. Financial stability was demonstrated through robust cash flow generation and a healthy balance sheet, supported by significant stock repurchase programs and a strong debt rating. Key initiatives like the 360º Health program and participation in the Blue Health Intelligence database underscore the company's commitment to improving care quality and member experience.

Elevance Health, Inc. (ELV), formerly WellPoint, Inc., reported substantial growth and strategic advancements in its 2005 annual report. The company solidified its position as the largest commercial health benefits provider in the U.S. with approximately 34 million members, driven by a significant increase in operating revenue (118% year-over-year) primarily due to the merger with WellPoint Health Networks Inc. (WHN). The acquisition of WellChoice, Inc. for $6.5 billion towards the end of 2005 further expanded its market presence, particularly in New York City. Elevance Health also demonstrated a commitment to shareholder value by exceeding its EPS growth target and continuing share repurchases. The company's financial performance was robust, with a 157% increase in net income year-over-year, reflecting successful integration of past mergers, disciplined pricing, and effective cost management, including a benefit expense ratio improvement. Looking ahead, the company remains focused on strategic acquisitions and organic growth to capitalize on economies of scale and evolving market demands, while navigating the complexities of the healthcare industry and regulatory landscape.

Elevance Health, Inc. (formerly WellPoint, Inc. after the November 30, 2004 merger of Anthem and WellPoint Health Networks Inc.) reported strong performance for the fiscal year ending December 31, 2004. The significant merger, valued at approximately $16 billion, has positioned the company as the largest publicly traded commercial health benefits provider in the U.S. by membership, serving over 27 million members. The company experienced substantial revenue growth driven by both organic membership increases across various customer segments like National Accounts and Individual/Small Group, and the inclusion of acquired businesses. Financially, the company demonstrated robust growth in premiums and administrative fees, reflecting the expanded scale and market reach post-merger. Despite increased benefit expenses due to higher costs in outpatient and pharmacy services, as well as the integration of new members, the company managed its selling, general, and administrative expenses effectively, leading to a significant increase in operating gain. The company's balance sheet remains strong, with substantial cash and investments, and a manageable debt-to-total capital ratio, indicating a solid financial foundation for future growth and strategic initiatives.

Elevance Health, Inc. (formerly Anthem, Inc.) in its 2003 10-K filing reported robust growth and strategic expansion, solidifying its position as a leading health benefits company. The company served over 11.9 million members across nine states, with significant membership increases driven by both organic growth and strategic acquisitions, most notably the acquisition of Trigon Healthcare, Inc. in July 2002. The company's strategy focused on promoting quality care through robust disease management programs and technology, enhancing product value with flexible and competitively priced offerings, and driving operational excellence. A key strategic initiative was the pending merger with WellPoint Health Networks Inc., announced in October 2003, which was expected to create a significantly larger and more diversified health benefits enterprise. Financially, the company demonstrated strong performance, with total operating revenue reaching $16.48 billion, and net income increasing by 41% to $774.3 million, reflecting effective cost management and growth across its business segments.

Elevance Health, Inc. (formerly Anthem, Inc.) reported strong performance for the year ended December 31, 2002, showcasing significant growth in total revenue and net income, largely driven by strategic acquisitions, notably the integration of Trigon Healthcare, Inc. The company's diversified product portfolio, including managed care plans like HMOs and PPOs, along with specialty products, serves approximately eleven million members across nine states. Anthem's focus on operational efficiency, expanding its geographic reach, and leveraging the Blue Cross Blue Shield brand strength positions it well for continued growth. The company also highlights its commitment to quality care through various medical management programs and initiatives. Financially, the company demonstrated robust revenue growth and improved profitability. Key financial highlights include a substantial increase in operating revenue, driven by premium growth and membership expansion, coupled with a favorable trend in benefit expense ratios. The company maintained a strong financial position and liquidity, with significant cash and investments. Future growth is expected to be fueled by organic expansion and potential strategic acquisitions, while the company remains committed to operational excellence and delivering value to its customers.